Thus, our previously published CD163 results [7] and current CCL17 results are consistent with an anti-inflammatory role of CD163 and CCL17 (M2 markers) as they are reduced in T2DM [7]. This evidence concerns the gene CCL17 and type 2 diabetes mellitus.